Table 2. Clinical Characteristic of Control and Experimental Groups a.
| Control Group | Experimental Group | P Value | |
|---|---|---|---|
| Type of Cancer | 0.67b | ||
| Respiratory | 1 (0.02) | 3 (0.08) | - |
| Gastrointestinal | 19 (52) | 15 (42) | - |
| Breast and Gynecology | 3 (0.08) | 2 (0.05) | - |
| Kidney | 3 (0.08) | 6 (0.17) | - |
| Skin | 3 (0.08) | 4 (0.11) | - |
| Others | 7 (0.19) | 5 (0.14) | - |
| Stage of Cancer | 0.55c | ||
| Primary | 12 (44) | 11 (36) | - |
| Metastatic | 15 (56) | 19(64) | - |
| Period of Chemotherapy | 0.46c | ||
| < 5 | 20 (55) | 26 (68) | - |
| 6-9 | 12 (33) | 8 (21) | - |
| > 10 | 4 (11) | 4 (11) | - |
| Interval of Chemotherapy | 0.82c | ||
| 1-3 week | 14 (37) | 12 (34) | - |
| 3 < | 24 (63) | 23 (66) | - |
| Treatment Regimen | 0.82c | ||
| Alkylating Agents | 3 (0.07) | 5 (0.13) | - |
| Antimetabolites | 8 (0.2) | 9 (0.23) | - |
| Mitotic Inhibitors | 21 (0.53) | 19 (0.49) | - |
| Topoisomerase Inhibitors | 8 (0.2) | 6 (0.15) | - |
a Data are Presented as No. (%).
b Chi square test.
c Fisher’s exact test.